Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Japan's health ministry has approved Optune Pax, a wearable Tumor Treating Fields device, combined with gemcitabine and nab-paclitaxel for unresectable locally advanced pancreatic cancer. The phase 3 PANOVA-3 trial showed a modest but significant overall survival improvement of 16.2 vs. 14.2 months over chemotherapy alone. The approval follows a similar FDA green light in February 2026.
Japan's Ministry of Health, Labour and Welfare has approved Optune Pax — a wearable device that delivers Tumor Treating Fields (TTFields) — for use alongside gemcitabine and nab-paclitaxel in adults with unresectable, locally advanced pancreatic cancer. The device works by emitting alternating electric fields that disrupt cancer cell division, offering a novel non-systemic approach to a notoriously difficult-to-treat disease. The approval follows the FDA's own authorization of Optune Pax in February 2026.
The decision was backed by the phase 3 PANOVA-3 trial, which enrolled 571 patients and compared TTFields plus chemotherapy against chemotherapy alone. Beyond survival gains, the combination also delayed pain progression — a meaningful quality-of-life benefit for patients with this aggressive cancer.
By the Numbers:
Why it matters: Locally advanced pancreatic cancer carries a grim prognosis with few effective options. Optune Pax's approval in Japan — following the U.S. — marks a meaningful step forward, offering clinicians a new first-line tool that improves survival and preserves quality of life without adding systemic toxicity.
